OptiBiotix Health - Proposed Director appointment and Director change
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Proposed Director appointment
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it intends to appoint Christopher Brinsmead CBE as a Director of the Company, subject to the completion of regulatory due diligence being carried out by the Company's Nomad.
Chris has worked in the pharmaceutical industry for over 30 years, holding executive leadership roles with ICI, and Zeneca, before becoming Chairman of AstraZeneca Pharmaceuticals
Advisory positions include independent advisor to the Prime Minister and other senior government ministers for life sciences (2010-2017) and advisor to Sodexo Healthcare (2010-2017). Chris is currently the Chairman of two companies - Scapa Plc and Proveca Ltd, and is a member of council at Imperial College.
Other non executive positions include UDG Healthcare plc (2017- 2019) and chairman of Consort Medical plc (2019-2020), a FTSE 350 company which was sold during Chris's leadership to Recipharm for
Chris will replace
A further announcement will be made in due course.
The Board of OptiBiotix would like to take this opportunity to thank Peter for his advice on brand strategy and helping OptiBiotix position its SlimBiome®, LPLDL® and WellBiome® brands in international markets, and his contribution to the Company's development.
The Company anticipate that there will be further additions and changes to the Board and management teams as it continues to grow sales, expand into international markets and commercialises its next generation products. "
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the content of this announcement.
For further information, please contact:
OptiBiotix Health plc
| || |
Contact via Walbrook below
| || |
Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Tel: 020 7220 0500
Walbrook PR Ltd
Mob: 07876 741 001
| || |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiﬁed by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reﬂect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
Quick facts: OptiBiotix Health PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE